cyrilzakka/clinical-trials huggingface dataset:
Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.


Eligibility Criteria:
Inclusion Criteria:

* Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;

  * Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
  * Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
* atopic dermatitis,
* prurigo,
* primary contact dermatitis or allergic
* urticaria,
* pharmacodermic,
* allergic vasculitis,
* dyshidrosis,

Exclusion Criteria:

* Patients being treated with antibiotics;
* Participation in clinical trials in the 12 months preceding the survey;
* Current treatment with immunosuppressants (eg, cyclosporine or methotrexate);
* Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
* Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion;
* Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
* Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
* Presence of secondary infections at the site of treatment, diagnosed clinically;
* Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
* Pregnant or lactating women;
* Chronic alcoholism;
* Patients with a history of hypersensitivity to any component of the formulas of the products under investigation;
* Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
* Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.
Acute Myeloid Leukemia Real World Treatment Patterns

Among patients with a diagnosis of AML who received non-intensive chemotherapy:

* Describe patient demographic and clinical characteristics
* Describe treatment patterns
* Describe effectiveness outcomes
* Evaluate tumor response


Eligibility Criteria:
Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record.
2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent:

   1. AZA
   2. GLAS
   3. VEN
3. Age ≥18 years at initial diagnosis of AML.

Exclusion Criteria:

Patients meeting any of the following criteria will not be included in the study:

1. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.
Cognitive Groove (Brought to You by GERAS DANCE)

The goal of this clinical trial is to determine the effect of a community-based rehabilitation intervention (Cognitive Groove, Brought to you by GERAS DANCE), compared to usual care, on clinical outcomes in community-dwelling older adults living with frailty. The main questions it aims to answer are:

1. In community-dwelling older adults living with frailty, is Cognitive Groove more effective than usual care in improving functional movement, physical performance and strength?
2. In community-dwelling older adults living with frailty is Cognitive Groove more effective than usual care in improving frailty status, fear of falling, balance confidence, mood, cognition, grip strength, activities of daily living, life space mobility, loneliness, and quality of life?
3. As a community-based rehabilitation intervention, is Cognitive Groove a cost-effective intervention embedded within the community for older adults living with frailty after 12-months?

Participants will participate in Cognitive Groove classes twice per week for 3 months or receive no intervention (usual care).


Eligibility Criteria:
Inclusion Criteria:

* Community-dwelling aged ≥65 years
* At high risk for mobility disability/functional limitations as assessed by the FRAIL Scale ≥2
* Able to ambulate independently (25 m) with or without an assistive device
* Able to follow two-step instructions
* Medical clearance from referring clinician, or for self-referrals, medical clearance from family physician to safely participate in exercise
* Can arrange transportation to the YMCA up to 2 times per week

Exclusion Criteria:

* Unable to speak or understand English
* Current regular participation in a structured exercise program or receiving active physical therapy services
* Severe cardiac or pulmonary disease
* Unstable angina or heart failure
* Severe osteoarthritis (e.g., awaiting joint replacement)
* Parkinson's disease or other progressive neurological disorder
* Receiving palliative care
* Travel/commitments requiring missing more than two weeks
Blood Pressure Responses to Different Exercise Modes in Coronary Artery Disease

The purposes of this study were to compare blood pressure responses of the same target heart rate on different exercise modes in patients with coronary artery diseases (CAD) and to compare the effects of blood pressure responses after exercise training.

The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. The subjects performed the treadmill or stationary bicycle exercise randomly.

Considering cardiopulmonary rehabilitation intensity is often setting by heart rate clinically, and only few study focused on exercise responses patients with CAD, the purposes of this study were to compare blood pressure responses of the same target heart rate on different exercise modes in patients with CAD and to compare the effects of blood pressure responses after exercise training.

This is a crossover trial study. The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode. The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.

Eligibility Criteria:
Inclusion Criteria:

* patients with coronary artery diseases who are referred to phase II cardiopulmonary rehabilitation exercise training.

Exclusion Criteria:

* patients with non-coronary artery diseases
* atrial fibrillation
* neurological or musculoskeletal problems
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet

The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of PKU with hyperphenylalaninemia (HPA) documented by at least one blood Phe measurement \>/=360 umol/L (6 mg/dL)
* Under dietary control with a Phe-restricted diet as evidenced by:· Estimated daily Phe tolerance \</=1000 mg/day
* At least 6 months of blood Phe control (mean level of \</=480 μmol/L) prior to enrolling in the study
* Aged 4 to 12 years inclusive at screening
* A blood Phe level \</=480 μmol/L at screening
* Female subjects of childbearing potential (as determined by the principal investigator) must have a negative blood or urine pregnancy test at entry (prior to the first dose). Note: All female subjects of childbearing potential and sexually mature male subjects must be advised to use a medically accepted method of contraception throughout the study. Female subjects of childbearing potential must be willing to undergo periodic pregnancy tests during the course of the study
* Willing and able to comply with all study procedures
* Willing to provide written assent (if applicable) and written informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures

Exclusion Criteria:

* Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study
* Prior history of organ transplantation
* Perceived to be unreliable or unavailable for study participation or have parents or legal guardians who are perceived to be unreliable or unavailable
* Use of any investigational agent within 30 days prior to screening, or requirement for any investigational agent or vaccine prior to completion of all scheduled study assessments
* ALT \> 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening
* Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
Relationships Among Physical and Psychological Status, Social Support, Resource Utilization, Supportive Care Needs in Patients With Gynecological Cancer

With the advancement of medical treatments and under the trend of prolonging the survival rate of gynecological cancer patients, the use of social resources and the need for supportive care are particularly important! In the past, studies on patients with gynecological cancer focused on the relation between physical and mental symptoms, intimate relationships, social support, and quality of life. There were few studies on the relationship between social support, resource utilization, and supportive care needs for this group of patients. Therefore, this study research will be conducted on these topics. The results of the study can confirm the current situation of gynecological cancer patients using social resources and the related factors that affect their supportive care needs, and can provide important empirical data for future social resource services and international research design content.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed by a physician as a patient with gynecological cancer
* Aged 20 or above, with clear consciousness and able to communicate in Mandarin and Taiwanese.
* After reading the consent form, accept the questionnaire.

Exclusion Criteria:

* Unconscious and unable to communicate verbally to complete the interview for this study
Resistance Training as Treatment of Achilles Tendinopathy

The use of eccentric resistance training as management of Achilles tendinopathy is widespread. The investigators have recently demonstrated that heavy slow resistance training was superior in the management of patellar tendinopathy.

Hypothesis: heavy slow resistance training is more effective than eccentric resistance training in the clinical management of Achilles tendinopathy.


Eligibility Criteria:
Inclusion Criteria:

* Unilateral Achilles tendon pain,
* Symptoms for at least three months,
* Ultrasonographical tendon abnormalities, AND
* Able to comply with both intervention arms.

Exclusion Criteria:

* Bilateral symptoms,
* Previous surgery below knee,
* Corticosteroid injections below the knee during past year,
* Hypercholesterol,
* Diabetes, OR
* Arthritis.
Social Egg Freezing: Will Health Professionals Offer it ?

In 2021, the revision of bioethics laws opened the door to elective egg freezing. This gives women, between their 29th and 37th birthdays, the opportunity to freeze their eggs in order to combat age decline fertility. However, communication about this new possibility has remained limited both toward women and their health professional.

Thus, the hypothesize of this study is that these professionals, namely physicians, gynecologists and midwives, are insufficiently aware of age-related fertility decline and unaware of the possibility of elective egg freezing.

This multicenter observational cross-sectional study whose objective will be:

* To assess the knowledge of these professionals in terms of age-related fertility decline.
* To measure their propensity to spontaneously broach the subject with their childless patients.
* To assess their knowledge and support for elective egg freezing. This study will be done using an online questionnaire that will be distributed in electronic format to all the health professionals concerned in the participating areas.

This study will provide valuable knowledge on the perception of elective egg freezing by health professionals, determine their training needs and motivate new information campaigns on this subject.

Eligibility Criteria:
Inclusion Criteria:

* Be a general practitioner, gynecologist or midwife in practice for at least one year
* Follow patients between 29 and 37 years old (for their contraception for example)

Exclusion Criteria:

* Have been practising for less than a year
* Have no patients aged between 29 and 37
Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases

Balance impairment is one of the most common disorders due to a neurological diseases. Sensor-based technologies may be useful for falls prevention and balance recovery during patients hospitalization. OAK Elderly Care System (Khymeia Group, Noventa Padovana, Italy) allows the assessment of fall risk, the centre of pressure and the execution of balance exercises in a virtual environment.

The aim of the study is to compare the therapy provided by means of the OAK Elderly Care System with conventional physiotherapy for balance rehabilitation in patients affected by stroke, Multiple Sclerosis (MS) and Parkinson Disease (PD).

OAK Elderly Care System consists of two independent balance boards and three sensors for the kinematic tracking of the trunk and lower limbs. These components allow the assessment of the centre of pressure and the execution of exercises in a virtual environment.

120 patients (40 stroke, 40 MS, 40 PK) hospitalized at 4 different italian hospitals, were enrolled according to inclusion and exclusion criteria and randomly assigned to two groups (i.e. intervention group, control group). Intervention group received 1 daily hour of technology-based treatment, while the control group underwent 1 daily hour of physiotherapy for balance rehabilitation, in addiction to 1 hour of conventional physiotherapy. Both treatments lasted 15 sessions. Before and after treatment balance, walking, daily living autonomy and pathology-specific features were assessed.

Eligibility Criteria:
Inclusion Criteria:

Common criteria:

* Berg Balance Scale \< 50/56;
* Ability to maintain the standing position with o without one support for 1 minute;
* Functional Independence measure \< 100/126;
* Barthel Index \< 80/100.

Stroke:

* Single ischemic stroke;
* Lesion occured after 2 and within 18 months;
* National Institute of Health Stroke Scale ≤ 14.

Parkinson:

* 1.5 \< Hoehn \& Yahr \< 3;
* Subitem "freezing when walking"of the UPDRS ≤ 2.

Multiple Sclerosis:

* Relapsing remitting or secondary progressive Multiple Sclerosis;
* Expanded Disability Status Scale ≤ 6.5.

Exclusion Criteria:

* Untreated epilepsy;
* Major depressive disorder;
* Fractures;
* Dementia;
* Ideomotor Apraxia;
* Neglect;
* Severe impairment of verbal comprehension;
* Severe acoustic and visual disorders.
Technical Feasibility of Routine Intraoperative Cholangiography During Elective Rigid-hybrid Transvaginal Natural Orifice Transluminal Endoscopic Cholecystectomy

While gold standard in the treatment of symptomatic gall stones is laparoscopic cholecystectomy with instruments introduced through multiple abdominal wall incisions, transvaginal access to the peritoneal cavity offers an alternative avoiding injury of the abdominal wall. Transvaginal hybrid-NOTES cholecystectomy has been demonstrated effective and safe. However it has not been demonstrated up-to-date if intraoperative cholangiography is feasible during such procedure. This observational case series describes success and technical feasibility of intraoperative cholangiography during transvaginal cholecystectomy. The investigators hypothesis is that cholangiography is feasible equal to conventional laparoscopic cholecystectomy.


Eligibility Criteria:
Inclusion Criteria:

* symptomatic gallstone disease
* age \> 18 years
* written informed consent

Exclusion Criteria:

* age \< 18 years
* not able to understand informed consent
* pregnancy
* vaginal atresia
* florid vaginal infection
* gynecological neoplasia
* allergy to Iod
* missing informed consents
* emergency procedure
Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis

By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.

In past, investigators summarized a method that was the severity and prognosis of pulmonary alveolar proteinosis (SPSP) to assess the severity and prognosis of patients with autoimmune pulmonary alveolar proteinosis (auto PAP). The SPSP included five aspects: smoking, symptom, PaO2, chest CT score at specific levels (aortic arch, carina, pulmonary vein confluence, and superior septal level) and DLCO %predicted. But the chest CT score only focused on range of lesions, and inaccurate. So, investigators plan to adopt new score which involves the assessing to range and density.

In the new Chest HRCT score, we added the density score. The average density of the lesions at a particular level of the patient's chest HRCT was measured by computer and classified into three degrees: mild (less than -400), moderate (greater than -400 and less than -100) and severe (greater than 100), denoted as 1 ', 2 'and3', respectively.

The range score of lung opacity was estimated using a five-point scale: no opacity = 0; opacity involving \< 25% of a region of hemithorax = 1; 25-50% = 2; 50-75% = 3; and ≥ 75% = 4.

The lesion score for each layer is equal to the density score multiplied by the range score. The chest HRCT score was calculated by summing the lung opacity scores of the four representative regions of each hemithorax, and divided into several level: no opacity = 0; ≤10 = 1; 11 - 20 = 2; 21 - 30 = 3; 31 -40 = 4; \> 40 = 5.

According to the new chest HRCT score, the SPSP will be updated to SPSP II. In this study, patients with auto PAP from three centers (Shanghai Lung Hospital, Peking Union Medical College Hospital and Nanjing Drum Tower Hospital) were enrolled to evaluate the severity of disease severity score (DSS), SPSP and SPSP II, respectively, to evaluate the pros and cons of different scores and their impact on prognosis.

About 30 newly diagnosed auto PAP patients were recruited, and were assess disease severity on the basis on SPSP II scores. According to SPSP II scores, appropriate treatment was used for the patients, who were followed up for 3 months.

Eligibility Criteria:
Inclusion Criteria:

* The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through pathology or bronchial alveolar lavage fluid (BALF).
* The patients are old than 18 year.
* .Every patient had a complete medical history, chest HRCT, pulmonary function and arterial blood gas analysis.
* The patients have high level antibody of GM-CSF in serum or BALF.

Exclusion Criteria:

* The patients had a congenital or secondary pulmonary alveolar proteinosis.
The Clinical Study Aims to Assess the Quality of Donor Livers Using Hyperspectral Imaging.

Based on hyperspectral imaging equipment, this project collected hyperspectral imaging data of donor livers, analyzed various parameters, investigated the detection capability of hyperspectral imaging for assessing donor liver quality, gathered patient prognosis information, examined the correlation between early postoperative complications and hyperspectral imaging data, and explored characteristic parameters for evaluating donor liver quality using hyperspectral imaging technology. The occurrence of early complications was predicted.

Hyperspectral imaging (HSI) is an advanced optical technology that combines spectroscopy and imaging, providing a non-destructive approach for clinical diagnosis. In recent years, hyperspectral imaging has emerged as a prominent research topic in the field of applied medicine. Liver transplantation is considered the most effective treatment for end-stage liver disease; however, the scarcity of donor livers and the growing number of patients awaiting transplantation pose significant challenges to global organ transplantation. The evaluation of donor livers has always been a focal point in liver transplantation. Currently, clinical evaluation relies heavily on subjective judgment by transplant physicians based on general appearance and touch assessments, along with clinical examinations and pathological biopsy results. Nevertheless, studies have demonstrated that these methods are not entirely reliable for assessing liver quality. Therefore, it is crucial to identify additional evaluation parameters and establish a convenient, reliable, and non-invasive method to assess donor liver quality. This study aims to analyze hyperspectral imaging data alongside clinical test data and recipient complications occurring between June 2022 to June 2024 to evaluate the quality of donor livers using hyperspectral imaging technology while exploring potential evaluation parameters.

Eligibility Criteria:
Inclusion Criteria:

1. Recipients ranged in age from 18 to 65
2. Donor age ≥ 18 years

Exclusion Criteria:

1. Recipients are younger than 18 years or older than 65 years
2. Donor younger than 18 years
3. Secondary liver transplantation.
4. Multiple organ transplantation.